SSA
RAPP

Schonfeld Strategic Advisors’s Rapport Therapeutics RAPP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-57,148
Closed -$1.7M – 2702
2025
Q3 		$1.7M Buy
+57,148
New +$1.02M 0.01% 1123

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Schonfeld Strategic Advisors's RAPP Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 57,148 shares — an estimated $1.7M sold.

Schonfeld Strategic Advisors first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $1.7M in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 57,148 Rapport Therapeutics shares in Q4 2025, an estimated $1.7M.
  • Schonfeld Strategic Advisors first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Rapport Therapeutics position peaked at $1.7M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.